Companies /Healthcare
Alignment Healthcare Inc
NASDAQ: ALHC Healthcare Plans
$7.42
▲ $0.06 (+0.80%) today
Markets open · 1:35pm ET

Alignment Healthcare (ALHC) Q3 2026 Earnings

Reported Oct 29, 2026, 4:01pm ET · SEC source
$-0.04
Miss −194.12%
EPS · est. $0.04 GAAP

GAAP diluted loss per share; no adjusted EPS disclosed. Quarter includes $17.5 million ($17,487 thousand) of equity-based compensation and higher medical costs from elevated appeals and disputes, catastrophic cases and skilled nursing; no litigation cost add-backs in the quarter (vs. $546 thousand prior year).

$1.4B
Beat +3.43%
Revenue · est. $1.3B
3 quarters
Consecutive EPS misses

How Did ALHC Stock React to Q3 2026 Earnings?

% change · around the report
−7%0+7%+14%Oct 29Oct 30report 4:01pm ETearnings−1.3%+0.8%
−7%0+7%+14%Oct 29Oct 30earnings−1.3%+0.8%
ALHC +0.8%S&P 500 −1.3%
−7%0+7%+14%Oct 29Oct 30report 4:01pm ETearnings−2.1%+0.8%
−7%0+7%+14%Oct 29Oct 30earnings−2.1%+0.8%
ALHC +0.8%NASDAQ −2.1%
−7%0+7%Oct 28Nov 3report 4:01pm ETearnings−1.2%−0.7%
−7%0+7%Oct 28Nov 3earnings−1.2%−0.7%
ALHC −0.7%S&P 500 −1.2%
−7%0+7%Oct 28Nov 3report 4:01pm ETearnings−2.6%−0.7%
−7%0+7%Oct 28Nov 3earnings−2.6%−0.7%
ALHC −0.7%NASDAQ −2.6%
−9.80%
Day of report
−3.71%
Next session
+0.96%
One week

Did ALHC Beat Earnings? Q3 2026 Results

No. Alignment Healthcare reported Q3 2026 earnings of $-0.04 a share on Oct 29, 2026, missing the $0.04 consensus estimate by 194.1%. Revenue was $1.4B against a $1.3B estimate.

Alignment Healthcare delivered a deeply split third quarter for 2026, posting revenue of $1.36 billion, up 36.7% year-over-year and beating the $1.31 billion consensus by 3.43%, while its GAAP loss per share of $0.04 missed the $0.04 analyst estimate by 194.12% as surging medical costs overwhelmed top-line momentum. The core problem was a sharp rise in the medical benefits ratio to 89.5%, roughly 240 basis points worse than a year earlier, driven by elevated appeals and disputes, catastrophic cases, and skilled nursing expenses, costs that pushed the company to a GAAP net loss of $8.05 million compared with net income of $3.73 million in the prior-year period; the quarter also carried $17.5 million of equity-based compensation. Adding to the backdrop, the company faces a whistleblower lawsuit alleging historical misclassification of operating expenses to inflate adjusted EBITDA, a cloud that hung over the print. Management raised full-year membership and revenue guidance to at least 305,000 members and $5.25 billion, respectively, but lowered adjusted EBITDA guidance to at least $100 million and warned of an adjusted EBITDA loss of as much as $28 million in the fourth quarter, assuming no benefit from corrective actions already underway.

Key Takeaways
  • Health plan membership up 31.2% year-over-year to about 301,200
  • Total revenue up 36.7% year-over-year to $1,358.3 million
  • Adjusted gross profit up 11.6% to $142.2 million
  • Medical benefits ratio rose about 240 bps to 89.5% on Part D seasonality changes, timing of clinical investments, elevated appeals and disputes, and higher catastrophic case and skilled nursing costs
  • SG&A rose to $136.4 million from $110.0 million
  • Adjusted EBITDA fell 32.8% to $21.8 million (1.6% margin)

“Our third-quarter membership and revenue growth demonstrate continued demand for Alignment's products and services, while medical trends ran higher than expected.”

Alignment Healthcare CEO, on the earnings call

What Is Alignment Healthcare's Outlook?

Alignment raised full-year 2026 membership and revenue guidance to reflect continued sales momentum. It lowered adjusted gross profit and adjusted EBITDA guidance to reflect higher medical costs in Q3. For Q4 2026, the company expects membership of no less than 305,000, revenue of no less than $1,316 million, adjusted gross profit of no less than $104 million, and adjusted EBITDA of no less than $(28) million. For full-year 2026, it expects membership of no less than 305,000, revenue of no less than $5,245 million, adjusted gross profit of no less than $575 million, and adjusted EBITDA of no less than $100 million. The revised guidance assumes no benefit from corrective actions underway.

ALHC YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$400.0M$800.0M$1.2B$993.7M$1.4BRevenue
$0$400.0M$800.0M$1.2BRevenue
ALHC income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $1.4B $993.7M +36.7%

ALHC Revenue by Segment

Earned Premiums$1.3B
Other Revenue$10.0M

Figures from SEC filings and company reports. Not investment advice.